** Drugmaker BioCryst Pharmaceuticals' BCRX.O shares fall 11% to $8.20
** Co posts Q4 net loss of 13 cents per share, compared with analysts' estimates of a loss of 6 cents per share, according to data compiled by LSEG
** Separately in a filing, co discloses it received a notice from India's Annora Pharma in January regarding Annora's submission of an application to the FDA seeking approval to manufacture, use or sell a generic version of BCRX's Orladeyo before the expiration of patents
** The letter alleges that the patents, which expire in 2039, are invalid
** Orladeyo is used to prevent attacks of hereditary angioedema, a rare genetic disorder that causes severe swelling in the body
** BCRX intends to vigorously defend its intellectual property rights protecting Orladeyo, it said
** Co posts Q4 revenue of $131.5 million on strong sales for Orladeyo, compared with analysts' estimates of $130.2 million
** Expects 2025 total revenue between $560 million and $575 million vs analysts' estimates $545 million
** BCRX rose 63% in the last 12 months
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。